Cardiol Therapeutics (CRDL) Cash from Restructuring (2020 - 2026)

Cardiol Therapeutics' Cash from Restructuring history runs 7 years deep, the most recent figure standing at $3448.4 for Q1 2026.

• Quarterly Cash from Restructuring fell 17.14% year-over-year to $3448.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15740.1 (down 14.37% YoY) and the FY2021 annual result came in at $10316.8, down 15.14% from the prior year.
• Cash from Restructuring was $3448.4 for Q1 2026 at Cardiol Therapeutics, down from $3988.5 in the prior quarter.
• Across five years, Cash from Restructuring topped out at $4927.6 in Q1 2024 and bottomed at $1024.4 in Q2 2023.
• A 5-year average of $3254.5 and a median of $3988.5 in 2025 frame the typical range for Cash from Restructuring.
• Annual changes were most pronounced in 2023 — Cash from Restructuring sank 46.32% — and 2024, when it jumped 354.37%.
• Cardiol Therapeutics' Cash from Restructuring stood at $1695.3 in 2022, then surged by 161.23% to $4428.6 in 2023, then climbed by 4.71% to $4637.3 in 2024, then decreased by 13.99% to $3988.5 in 2025, then retreated by 13.54% to $3448.4 in 2026.
• Business Quant data shows CRDL's Cash from Restructuring at $3448.4 in Q1 2026, $3988.5 in Q3 2025, and $4141.2 in Q2 2025.